Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) has appointed Alex Rothwell as its new Chief Financial Officer, replacing retiring CFO Bruce Cousins, who will remain as a consultant for the transition period. Rothwell, who previously served as Eupraxia's CFO from 2018-2021, brings over 25 years of experience in capital markets and investment banking.
Rothwell's background includes leadership roles at Canadian investment banks, including serving as President and Executive Director of Macquarie Capital Markets Canada. Throughout his career, he has helped raise billions in funding through various structures from early-stage investments to IPOs. He holds a Bachelor of Chemical Engineering from McGill University and an MBA from the Ivey School of Business.
The new CFO expressed optimism about Eupraxia's potential, particularly highlighting EP-104GI for Eosinophilic Esophagitis treatment and EP-104IAR for osteoarthritis knee pain.
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) ha nominato Alex Rothwell come nuovo Chief Financial Officer, sostituendo il CFO in pensione Bruce Cousins, che rimarrà come consulente durante il periodo di transizione. Rothwell, che ha precedentemente ricoperto il ruolo di CFO di Eupraxia dal 2018 al 2021, porta con sé oltre 25 anni di esperienza nei mercati dei capitali e nell'investment banking.
Il background di Rothwell include ruoli di leadership in banche d'investimento canadesi, tra cui la posizione di Presidente e Direttore Esecutivo di Macquarie Capital Markets Canada. Nel corso della sua carriera, ha contribuito a raccogliere miliardi in finanziamenti attraverso varie strutture, dagli investimenti in fase iniziale alle IPO. Ha conseguito una laurea in Ingegneria Chimica presso l'Università McGill e un MBA presso la Ivey School of Business.
Il nuovo CFO ha espresso ottimismo riguardo al potenziale di Eupraxia, evidenziando in particolare EP-104GI per il trattamento dell'esofagite eosinofila e EP-104IAR per il dolore al ginocchio da osteoartrite.
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) ha nombrado a Alex Rothwell como su nuevo Director Financiero, reemplazando al CFO saliente Bruce Cousins, quien permanecerá como consultor durante el período de transición. Rothwell, quien se desempeñó anteriormente como CFO de Eupraxia de 2018 a 2021, aporta más de 25 años de experiencia en mercados de capitales y banca de inversión.
El historial de Rothwell incluye roles de liderazgo en bancos de inversión canadienses, incluyendo su cargo como Presidente y Director Ejecutivo de Macquarie Capital Markets Canada. A lo largo de su carrera, ha ayudado a recaudar miles de millones en financiamiento a través de diversas estructuras, desde inversiones en etapas tempranas hasta IPOs. Tiene una licenciatura en Ingeniería Química de la Universidad McGill y un MBA de la Ivey School of Business.
El nuevo CFO expresó optimismo sobre el potencial de Eupraxia, destacando particularmente EP-104GI para el tratamiento de la esofagitis eosinofílica y EP-104IAR para el dolor de rodilla por osteoartritis.
유프락시아 제약 (NASDAQ: EPRX) (TSX: EPRX)가 알렉스 로스웰을 새로운 최고 재무 책임자로 임명하였으며, 은퇴하는 CFO 브루스 커즌스를 대신하게 됩니다. 커즌스는 전환 기간 동안 컨설턴트로 남아 있을 것입니다. 로스웰은 2018년부터 2021년까지 유프락시아의 CFO를 역임했으며, 자본 시장 및 투자 은행 분야에서 25년 이상의 경험을 보유하고 있습니다.
로스웰의 배경에는 캐나다 투자 은행에서의 리더십 역할이 포함되어 있으며, Macquarie Capital Markets Canada의 사장 및 전무 이사를 역임했습니다. 그의 경력 동안 그는 초기 투자에서 IPO에 이르기까지 다양한 구조를 통해 수십억 달러의 자금을 조달하는 데 기여했습니다. 그는 맥길 대학교에서 화학 공학 학사 학위를 받았고, 아이비 경영대학원에서 MBA를 취득했습니다.
새로운 CFO는 유프락시아의 잠재력에 대해 낙관적인 입장을 표명하며, 특히 EP-104GI를 호산구 식도염 치료에, EP-104IAR를 골관절염 무릎 통증 치료에 강조했습니다.
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) a nommé Alex Rothwell comme nouveau directeur financier, remplaçant le CFO sortant Bruce Cousins, qui restera consultant pendant la période de transition. Rothwell, qui a précédemment été CFO d'Eupraxia de 2018 à 2021, apporte plus de 25 ans d'expérience dans les marchés de capitaux et la banque d'investissement.
Le parcours de Rothwell comprend des postes de direction dans des banques d'investissement canadiennes, y compris celui de président et directeur exécutif de Macquarie Capital Markets Canada. Tout au long de sa carrière, il a contribué à lever des milliards en financement à travers diverses structures, allant des investissements en phase initiale aux introductions en bourse. Il est titulaire d'une licence en ingénierie chimique de l'Université McGill et d'un MBA de l'Ivey School of Business.
Le nouveau CFO a exprimé son optimisme quant au potentiel d'Eupraxia, mettant particulièrement en avant EP-104GI pour le traitement de l'œsophagite éosinophilique et EP-104IAR pour la douleur au genou due à l'arthrose.
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) hat Alex Rothwell als neuen Chief Financial Officer berufen, der den scheidenden CFO Bruce Cousins ersetzt, der während der Übergangszeit als Berater bleibt. Rothwell, der zuvor von 2018 bis 2021 CFO von Eupraxia war, bringt über 25 Jahre Erfahrung in den Kapitalmärkten und im Investment Banking mit.
Rothwells Hintergrund umfasst Führungspositionen bei kanadischen Investmentbanken, darunter die Rolle des Präsidenten und geschäftsführenden Direktors von Macquarie Capital Markets Canada. Im Laufe seiner Karriere hat er geholfen, Milliarden an Finanzierungen durch verschiedene Strukturen zu beschaffen, von frühen Investitionen bis hin zu IPOs. Er hat einen Bachelor-Abschluss in Chemieingenieurwesen von der McGill University und einen MBA von der Ivey School of Business.
Der neue CFO äußerte Optimismus über das Potenzial von Eupraxia und hob insbesondere EP-104GI zur Behandlung von eosinophiler Ösophagitis und EP-104IAR bei Knieschmerzen durch Osteoarthritis hervor.
- Appointment of experienced CFO with previous company knowledge and extensive capital markets expertise
- Strong track record in raising capital and executing deals
- Continuity maintained through transition period with outgoing CFO staying as consultant
- None.
- Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role
Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.
"Having previously served as Eupraxia's CFO, and after that as our capital markets consultant, we are delighted to have Alex return and take over from Bruce. I believe his public markets and deal expertise, and his deep familiarity with Eupraxia and its shareholders, will make Alex a key contributor to our senior leadership team as Eupraxia advances its programs in EP-104GI and EP-104AR," said James Helliwell, Chief Executive Officer of Eupraxia. "On behalf of our board of directors, I'd like to thank Bruce for his leadership and many important contributions to Eupraxia's success including the Company's recent Nasdaq listing, and his efforts strengthening our balance sheet, which gives us a solid foundation to build on."
Based in
In 1995, he began his capital markets career in institutional equities and merger arbitrage, establishing himself over the next decade in various leadership roles at leading Canadian investment banks. He was appointed President and Executive Director of Macquarie Capital Markets Canada and ran its equities business for seven years before moving to
Over the course of his career, he has advised public and private companies on their growth and acquisition strategies and associated funding requirements and has raised billions of dollars for them in structures ranging from early-stage investment rounds to large IPOs and follow-on offerings.
Mr.
"I believe that Eupraxia is in an excellent position to create significant value for shareholders, and I'm very focused on helping drive that process. There is significant unrealized - and unrecognized - potential in the assets, and I have confidence that we can deliver on that potential for patients and shareholders," said Alex Rothwell, new Chief Financial Officer of Eupraxia. "EP-104GI has an opportunity to be the leading treatment for Eosinophilic Esophagitis, and associated conditions such as strictures. Additionally, we anticipate that EP-104IAR, for the treatment of pain due to osteoarthritis of the knee, can become a key therapy to treat this large patient population, and that its market can be materially expanded by use in other joint areas."
About Eupraxia
Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy, and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease, and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of Eosinophilic Esophagitis ("EoE"). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "aims", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company's CFO succession; the Company's business strategy and growth potential, including the ability to create significant shareholder value; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-cfo-succession-302378659.html
SOURCE Eupraxia Pharmaceuticals Inc.
FAQ
Who is the new CFO of Eupraxia Pharmaceuticals (EPRX) as of February 2025?
What is Alex Rothwell's previous experience with Eupraxia (EPRX)?
What are the key drug candidates mentioned by Eupraxia's (EPRX) new CFO?
What significant corporate milestone did the outgoing EPRX CFO Bruce Cousins achieve?
